Comparing oncological outcomes of laparoscopic vs open radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity score-matched analysis.
RNU
UTUC
Upper tract urothelial carcinoma
laparoscopic
open
radical nephroureterectomy
Journal
Arab journal of urology
ISSN: 2090-598X
Titre abrégé: Arab J Urol
Pays: United States
ID NLM: 101562480
Informations de publication
Date de publication:
04 Sep 2020
04 Sep 2020
Historique:
entrez:
25
3
2021
pubmed:
26
3
2021
medline:
26
3
2021
Statut:
epublish
Résumé
To compare oncological outcomes of open (ORNU) and laparoscopic radical nephroureterectomy (LRNU) after controlling for preoperative patient-derived factors. We evaluated a multi-institutional collaborative database composed of 3984 patients diagnosed with upper tract urothelial carcinoma (UTUC) treated with RNU between 2006 and 2018. To adjust for potential selection bias, propensity score matching adjusted for age, gender and American society Anesthesiology (ASA) score was performed with one ORNU patient matched to one LRNU patient. Uni- and multivariable Cox regression evaluating the risk of overall recurrence, cancer-specific mortality (CSM) and overall mortality (OM) in the overall population and after propensity matching were performed. In total, 3984 patients underwent RNU, of these 3227 (81%) patients were treated with ORNU and 757 (19%) patients with LRNU. Within a median follow-up of 62 months, 1276 recurrences, 844 CSMs and 1128 OMs were recorded. On multivariable analyses, the LRNU approach was associated with an increased risk of overall recurrence (hazard ratio [HR] 1.26, 95% confidence interval [CI] 1.03-1.54; Our present data suggest that even if the type of approach to RNU was associated with different survival outcomes considering the overall population, this difference vanished when adjusted for potential confounders in propensity matching analyses. Therefore, we found that LRNU is not inferior to the ORNU approach for the treatment of UTUC. ASA: American Society of Anesthesiology; CIS: carcinoma
Identifiants
pubmed: 33763246
doi: 10.1080/2090598X.2020.1817720
pii: 1817720
pmc: PMC7954493
doi:
Types de publication
Journal Article
Langues
eng
Pagination
31-36Informations de copyright
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
J Clin Oncol. 2013 Apr 10;31(11):1422-7
pubmed: 23460707
Eur Urol Focus. 2019 Mar;5(2):205-223
pubmed: 29154042
BJU Int. 2019 Nov;124(5):738-745
pubmed: 30908835
Eur Urol. 2009 Sep;56(3):520-6
pubmed: 19560259
J Urol. 2018 May;199(5):1149-1157
pubmed: 29158104
Eur Urol. 2012 Apr;61(4):715-21
pubmed: 22209172
Dis Markers. 2019 Sep 3;2019:7386140
pubmed: 31565103
World J Urol. 2017 Feb;35(2):251-259
pubmed: 27272502
Eur Urol. 2018 Jan;73(1):111-122
pubmed: 28867446
World J Urol. 2017 Oct;35(10):1541-1547
pubmed: 28247066
BJU Int. 2011 Aug;108(3):406-12
pubmed: 21078048
World J Urol. 2017 Jul;35(7):1073-1080
pubmed: 27830374
J Endourol. 2016 May;30(5):520-5
pubmed: 26669358
Eur Urol Oncol. 2020 Dec;3(6):756-763
pubmed: 31395480
BJU Int. 2018 Feb;121(2):252-259
pubmed: 28940605
Eur Urol. 2012 Apr;61(4):818-25
pubmed: 22284969
J Urol. 2020 Jun;203(6):1075-1084
pubmed: 31479406
World J Urol. 2016 Jun;34(6):859-69
pubmed: 26497823
Eur Urol Focus. 2019 Mar;5(2):224-241
pubmed: 29158169
Eur Urol. 2011 Oct;60(4):703-10
pubmed: 21684068